Kiluma Biosciences is advancing next-generation molecular diagnostics designed to identify cancer-associated biological signals earlier than traditional approaches. By integrating biomarker discovery, liquid biopsy, artificial intelligence, and precision molecular analysis, the InterceptIQ™ Platform aims to transform how cancer is detected, studied, and ultimately managed.
Global cancer impact
Nearly 10 million
people die from cancer every year worldwide.
Cancer remains the second leading cause of death globally.
Cancer remains one of the world's greatest healthcare challenges — not simply because it is difficult to treat, but because it is often detected too late.
For aggressive cancers such as pancreatic cancer, the opportunity for effective intervention is frequently lost before symptoms appear. By the time most patients receive a diagnosis, the disease has often progressed beyond the earliest stages when treatment options may be more effective.
Kiluma Biosciences was founded on the belief that molecular changes associated with cancer begin long before clinical symptoms emerge. Our mission is to advance innovative blood-based diagnostics capable of identifying those biological signals earlier, supporting future opportunities for earlier clinical evaluation, research, and precision medicine.
We believe the future of oncology will increasingly depend on detecting disease biology — not simply responding to disease after symptoms develop.
To develop next-generation blood-based molecular diagnostics that enable earlier detection of cancer through precision biomarker discovery, liquid biopsy technologies, and artificial intelligence. We are committed to advancing innovative diagnostic solutions that support clinicians, researchers, and patients in the pursuit of earlier, more informed cancer detection.
A future where cancer is identified at its earliest biological stages — before symptoms appear and when opportunities for clinical intervention may be greatest. Beginning with pancreatic cancer, Kiluma is building the InterceptIQ™ Platform to expand across multiple oncologic diseases.
We translate breakthrough science into clinically meaningful technologies through rigorous research, scientific excellence, and disciplined execution — helping shape the future of cancer detection.
From a single blood sample to molecular intelligence — an integrated pathway designed to surface cancer-associated signals earlier.
Step 01
A single peripheral blood draw.
Step 02
Non-invasive access to circulating disease signals.
Step 03
Fragmented tumor and tissue DNA in plasma.
Step 04
Methylation and regulatory state of cancer biology.
Step 05
Pattern recognition across orthogonal molecular layers.
Step 06
An integrated readout of disease biology.
Step 07
Surfacing cancer-associated signals sooner.
Pancreatic cancer remains one of the deadliest malignancies because it is often diagnosed after symptoms develop and the disease has significantly progressed.
Kiluma Biosciences is initially focused on pancreatic cancer because earlier molecular detection has the potential to meaningfully change how this devastating disease is investigated and managed.
While pancreatic cancer is our initial focus, our long-term vision is to expand the InterceptIQ™ Platform across additional oncology indications.
~13%
5-year survival rate
<20%
Detected early enough for surgery
~52K
U.S. deaths each year
#3
Leading cause of cancer death by 2030 (projected)
Learn more about the science driving Kiluma Biosciences and the team behind it.
